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Abstract Protection against xenobiotic insult, including cancer
chemoprotection, can be achieved by a variety of natural and
synthetic compounds belonging to over 20 different classes of
chemicals. They all induce or activate drug-metabolizing
enzymes. The discovery of a new class of activator is currently
reported. Sodium fluoride activated the phase I ethoxyresorufin-
O-deethylase (to 240%) and pentoxyresorufin-O-depentylase (to
156%), and the phase II glutathione transferase to 120% of the
basal activities in rat hepatoma-derived Fa32 cells. It is,
therefore, a bifunctional enzyme activator. A time- and
concentration-dependent activation was observed. A possible
impact of the daily fluoride uptake from drinking water is
suggested.
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1. Introduction
Protection against toxic insult, including cancer chemopre-
vention, can be achieved by a wide variety of compounds
belonging to over 20 di¡erent classes of chemicals [1]. They
include both natural and synthetic compounds such as poly-
cyclic aromatic hydrocarbons, £avonoids, azo dyes, isothio-
cyanates, diterpenes, phenolic antioxidants, indoles, unsatu-
rated lactones, 1,2-dithiol-3-thiones, and thiocarbamates [1].
All of these chemicals share the property of inducing electro-
phile-processing phase II enzymes, e.g. glutathione transferase
(GST), which is a major protective mechanism [2^4]. Phase I
enzymes, mainly cytochrome P450-dependent enzymes, are
often activated by the same chemicals. Talalay et al. have
de¢ned monofunctional inducers as compounds that selec-
tively induce only phase II enzymes and bifunctional inducers
that induce both phase I and phase II enzymes [5,6].
Metabolic activity includes the biotransformation and de-
toxi¢cation of xenobiotics and is one of the major functions
of the liver. Reduced glutathione (GSH) and phase II enzymes
play an important role in these phenomena. During a series of
cytotoxicity assays it was observed that sodium £uoride be-
came nine times more toxic in GSH-depleted cells (unpub-
lished). The in£uence of sodium £uoride on drug-metabolizing
enzymes was, therefore, further investigated in Fa32 cells.
Sodium £uoride is used for several purposes: as an insecticide
and in many pesticide formulations, as a steel degassing agent,
as a disinfectant for fermentation apparatus, and so on [7].
Humans are mainly exposed to £uorides by the £uoridation of
drinking water and by dental products. This sometimes causes
problems, especially in children [8].
Established Fa32 cells are derived from a rat hepatoma [9].
We previously demonstrated that the endogenous GSH con-
tent interacts with the cytotoxicity of metals in Fa32 cells, and
deduced the presence of the GSH biosynthetic enzyme Q-glu-
tamylcysteine synthetase from the e¡ect of the speci¢c inhib-
itor L-buthionine-S,R-sulfoximine on the endogenous GSH
content [10]. Earlier, the cytosolic GSTs in Fa32 cells were
shown to be comparable to those in rat liver, except that the
hepatoma-speci¢c GST 7-7 is an additional enzyme in the
cultured cells [11]. Since also the GST activation by pheno-
barbital and butylated hydroxyanisole in Fa32 cells closely
resembles that in rat liver (unpublished), these cells are con-
sidered a valuable alternative model for the investigation of
GST-dependent metabolic interactions in rat liver.
2. Materials and methods
Established Fa32 cells were provided by Prof. Szpirer (UniversiteŁ
Libre de Bruxelles, Brussels, Belgium). The cells were cultured in
Dulbecco’s modi¢ed Eagle’s medium, supplemented with 10% fetal
calf serum, 100 units/ml penicillin, and 100 Wg/ml streptomycin (com-
plete medium).
The cytotoxicity was measured using the slightly modi¢ed [12] neu-
tral red uptake inhibition assay [13]. Brie£y, 6U104 cells were seeded
in each of the 64 wells of a microtiter plate (Nunc, Roskilde, Den-
mark). After 24 h the cells were treated with di¡erent concentrations
of freshly prepared sodium £uoride in complete medium (8 wells/con-
centration) for 24 h or 72 h. The toxicity was established by the
determination of the NI50, i.e. the concentration of test compound
required to induce a 50% inhibition in neutral red uptake compared
to control cells. The 50% inhibitory concentrations were extrapolated
from dose-response e¡ect curves by linear regression analysis.
For measuring the phase II GST activity nearly con£uent Fa32
monolayers were treated with sodium £uoride in complete medium
in 10 cm Petri dishes for 3 days, using 11 ml per Petri dish. Homog-
enization and cytosol preparation were carried out as described [11].
The GST activity was measured with 1-chloro-2,4-dinitrobenzene as
the second substrate [14]. The speci¢c activity is expressed in nmol/
min/mg protein. The proteins were measured by the Lowry method.
For the determination of the GST subunit pattern, GST in the cytosol
obtained from six Petri dishes was puri¢ed by GSH a⁄nity chroma-
tography [11]. The GST subunit composition was analyzed by using
HPLC on a narrow-bore Vydac 30 nm C18 reverse-phase column
(250U2.1 mm), eluted at a £ow rate of 0.25 ml/min [10].
In order to measure the phase I cytochrome P450 enzymes P450IA1
(EROD; 7-ethoxyresoru¢n-O-deethylase) and P450IIB1 (PROD; 7-
pentoxyresoru¢n-O-depentylase) [15], 60 000 cells/well were seeded in
six wells of ¢ve rows (A^E) of a titer plate. Two additional wells in
each row received only 200 Wl complete medium without cells and
were used for background subtraction later on. After 24 h the ¢ve
wells in the ¢rst three columns received fresh complete medium and
the cells in the remaining wells were treated for 24 h or 72 h with
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di¡erent concentrations of sodium £uoride. EROD and PROD activ-
ities were further measured essentially as described [16]. The cells were
washed with 200 Wl PBS/well. The assay was started by adding 100 Wl/
well of complete medium containing 8 WM 7-ethoxyresoru¢n or 15
WM 7-pentoxyresoru¢n, supplemented with 10 WM dicoumarol to pre-
vent further metabolism of the resoru¢n formed by the cytosolic en-
zyme diaphorase [17]. After 3 h at 37‡C, a 75 Wl aliquot of cell me-
dium was transferred to another titer plate. At this stage 75 Wl of a 0^
0.6 WM resoru¢n standard concentration range, also prepared in com-
plete medium, was added in the eight wells of rows F^H; 25 Wl with
15 Fishman units of L-glucuronidase and 120 Roy units of arylsulfa-
tase (Boehringer, Mannheim, Germany) in 0.1 M sodium acetate bu¡-
er, pH 4.5, was added to both the samples and the standards. The
plates were covered with aluminum foil and shaken at room temper-
ature. After 2 h, 200 Wl ethanol were added to each well, and the
plates were centrifuged at 3000 rpm for 10 min. After transfer of
200 Wl supernatant to a new titer plate, the £uorescence units (FU)
were measured at 600 nm emission with excitation at 535 nm using a
Dynatech Fluorolite 1000 £uorescence microplate reader. Higher, de-
viating £uorescence values were measured for the wells in the ¢rst row
(row A); these were therefore not used. The £uorescence was linear
within the used standard range.
The protein content was measured after the 3 h incubation period
with the phase I substrates (see above). The wells were rinsed twice
with 200 Wl PBS, and treated with 100 WM 0.1% Triton X-100 in 50
mM sodium borate bu¡er, pH 9.0. After incubation for 1 h at 37‡C,
30 Wl freshly prepared 1 mM 3-(4-carboxybenzoyl)-quinoline-2-car-
boxaldehyde (CBQCA)/6.7 mM KCN in 50 mM sodium borate bu¡-
er, pH 9.0, was added to each well [18]. CBQCA is virtually non-
£uorescent in aqueous solution and reacts with protein amines in
the presence of cyanide [19]. The titer plates were covered with alu-
minum foil and shaken at room temperature for 1 h. The £uorescence
was measured at 530 nm emission with excitation at 485 nm using a
Dynatech Fluorolite 1000 £uorescence microplate reader. To obtain
sample protein concentrations the FU were calibrated against a bo-
vine serum albumin standard curve prepared and assayed as the sam-
ples, using the wells of the three bottom rows (F^H). These protein
measurements also allowed us to establish the relative toxicity of
sodium £uoride by the determination of the PI50. This is the concen-
tration of test compound required to induce a 50% reduction of total
protein content, as compared to the control cells.
The experiments were performed three times. Mean values þ stand-
ard deviations are given.
3. Results
The sensitivity of the Fa32 cells towards sodium £uoride
was ¢rst examined by the neutral red uptake inhibition assay
(Fig. 1a). After 24 h a NI50 of 2.00 þ 0.09 mM sodium £uoride
was observed, and after 72 h a NI50 of 1.20 þ 0.06. These
pro¢les were afterwards compared with the total protein con-
tents, measured for the calculation of the speci¢c enzyme ac-
tivities (Fig. 1b). The PI50 values thus obtained were
1.96 þ 0.05 mM after 24 h and 1.21 þ 0.04 mM after 72 h.
Consequently, the cytotoxicity values of both methods corre-
sponded very well.
The in£uence of sodium £uoride on the phase II GST ac-
tivity was then investigated. A concentration-dependent acti-
vation was observed (Fig. 2), with a maximal activation of
20% above the control at a concentration of 1.20 mM sodium
£uoride. At higher concentrations sodium £uoride became too
toxic. Since Fa32 cells have several GST isoenzymes, as is the
case in rat liver [11], the GST subunit composition was ana-
lyzed by HPLC. However, no speci¢c activation of any GST
subunit was observed (results not shown). This means that all
GST isoenzymes were activated to the same degree.
The cytochrome P450-dependent EROD and PROD were
measured directly in the tissue culture plates. A maximal,
concentration-dependent, stimulation of 240% of the control
EROD was observed after 24 h sodium £uoride treatment
(Fig. 3a). PROD was stimulated less, to 156% of the control.
After 72 h EROD was poorly but signi¢cantly enhanced to
111% of the control, PROD being increased more, to 135%
(Fig. 3b). Also for the phase I enzymes sodium £uoride be-
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Fig. 1. Cytotoxicity of sodium £uoride in Fa32 cells, as measured
by neutral red uptake (a) and total protein content (b). The cells
were treated for 24 h (F) or 72 h (b).
Fig. 2. The in£uence of sodium £uoride on the speci¢c glutathione
transferase activity in Fa32 cells after 72 h. Speci¢c activity in the
control cells : 448 þ 51 nmol/min/mg protein.
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came too toxic at the highest concentrations, as re£ected by
the declining EROD and PROD activities in Fig. 3b.
4. Discussion
The activation of phase II GST is much lower than that by
the strongest GST activator trans-stilbene oxide in mouse liver
[20]. Using the same substrate as in our experiments GST
increases of 171% with the classical activator phenobarbital,
145% with 2-methylcholanthrene, and 130% with 2,3,7,8-tet-
rachlorodibenzo-p-dioxin were found in rat liver [21]. Sulfo-
raphane, an aliphatic isothiocyanate from broccoli, was de-
scribed as an activator of phase II detoxi¢cation enzymes [22]
and was shown to signi¢cantly inhibit 7,12-dimethylbenz[a]an-
thracene-induced mammary carcinogenesis in rats [23]. This
activator and its recently described synthetic analogue, sulfor-
amate [( þ )-4-methylsul¢nyl-1-(S-methyldithiocarbamyl)-bu-
tane], increase the GST activity in mouse liver to respectively
114 and 111%, but have a higher e¡ect in mammary glands
[24]. Two other recently described phase II drug-metabolizing
enzyme activators, quinoline and isoquinoline, enhance the
GST activity in rat liver to 120% of that in control rats
[25]. The sodium £uoride activation of GST we found in
Fa32 cells (Fig. 2) is very well comparable with the latter
one [25].
Fa32 cells have a higher EROD than PROD activity, as is
the case in rat hepatocytes [16]. A speci¢c EROD activity of
0.13 þ 0.05 nmol/mg protein/3 h was found in human hepato-
ma-derived HepG2 cells [26]. About twice this activity was
found in Fa32 cells (Fig. 3). Benzo[a]anthracene, 2,3-benzo-
£uorene, benzo[a]pyrene, 7-methylbenzo[a]anthracene, and
pyrene increased the concentration-dependent EROD activity
in HepG2 cells, but other polycyclic aromatic hydrocarbons
and organochlorine compounds, which have mutagenic or
carcinogenic activity, did not [26]. Phase I enzymes are always
more activated than phase II enzymes [2^5] which was also
the case for sodium £uoride in Fa32 cells (Figs. 2 and 3).
Sodium £uoride behaves as a bifunctional activator [5,6] in
Fa32 cells, since both phase I and phase II enzymes are acti-
vated.
Two di¡erences between sodium £uoride and the known
activators have to be mentioned. First, the inorganic com-
pound sodium £uoride has a chemically very simple structure,
in contrast to the other known activators [1,24^26]. Secondly,
sodium £uoride is used on a large scale, albeit in low concen-
trations. Because of its ability to reduce the development of
dental caries, the £uoridation of drinking water is a general
practice in the USA. This measure is accepted and recom-
mended by health authorities and dentists [27]. Exposure to
other inducers and/or activators is rather occasional or acci-
dental. It would be interesting to investigate the impact of the
daily £uoride consumption on the levels of phase I and II
enzymes, and hence on the probably higher resistance against
xenobiotic insult.
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Fig. 3. The in£uence of sodium £uoride on the speci¢c EROD (O)
and PROD (E) activity in Fa32 cells after 24 h (a) and 72 h (b).
Speci¢c activities in the control cells were for EROD: 3.07 þ 0.09
nmol/mg protein/3 h and for PROD: 1.42 þ 0.16 nmol/mg protein/
3 h.
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